The RAS-RAF-MEK1/2-ERK1/2 (RAS/MAPK) signalling pathway is frequently dysregulated in human cancers, often by mutations in BRAF or RAS genes and therefore is an important node for development of novel oncology compounds. The gene discussed is MAP2K1; the disease is cancer.